This Poster presentation is under embargo until 9 September 2026, as per congress regulations.

Please subscribe using the button below to receive a notification when the material becomes available.

Register for email alerts

 

 

Publication
  • SOHO •
  • 9 September, 2026 •
  • •

Real-world Treatment Patterns and Outcomes in Patients with Myelofibrosis Treated First-line with Pacritinib or Ruxolitinib

James Rossetti, Douglas Tremblay, Abiola Oladapo, Michael Marrone, Caleb Paydar, Djibril Liassou, Sarah Buckley, Purvi Suthar, Adina Geprifti, Michael Vredenburg , Bruce Feinberg, Naveen Pemmaraju

Publication
  • EHA •
  • 13 June, 2026 •
  • •

Consistency of Response by Baseline Platelet Count in Pacritinib-treated patients in the Real World: MY-PAC Analysis

James Rossetti, Douglas Tremblay, Abiola Oladapo, Michael Marrone, Caleb Paydar, Djibril Liassou, Sarah A. Buckley, Purvi Suthar, Adina Geprifti, Michael Vredenburg , Bruce Feinberg, Naveen Pemmaraju

Publication
  • ASCO •
  • 1 June, 2026 •
  • •

Treatment Patterns and Outcomes in Pacritinib-treated Patients with and higher platelet count: MY-PAC Study

Douglas Tremblay, Abiola Oladapo, Michael Marrone, Puja Aggarwal, Caleb Paydar, Djibril Liassou, Purvi Suthar, Adina Geprifti, Michael Vredenburg , Bruce Feinberg

Publication
  • ASH •
  • 8 December, 2025 •
  • •

Treatment patterns and outcomes in patients with myelofibrosis treated with pacritinib following a switch from ruxolitinib: The MY-PAC Study

Douglas Tremblay, Abiola Oladapo, Michael Marrone, Puja Aggarwal, Caleb Paydar, Djibril Liassou, Purvi Suthar, Adina Geprifti, Michael Vredenburg , Bruce Feinberg, James Rossetti, Naveen Pemmaraju

Publication
  • ASH •
  • 8 December, 2025 •
  • •

Incidence, prevalence, and clinical outcomes of myelofibrosis with and without cytopenia in the United States

Aaron T Gerds, Lindsay AM Rein, Nicole M Engel-Nitz, Michael Marrone, Jeffrey McPheeters, Abiola Oladapo, Purvi Suthar, Michael Vredenburg , Yong Zhu, Lucia Masarova

Sign up for alerts